Experts unpack BTK inhibitor use for relapsed primary CNS lymphoma, sharing Japan and Taiwan real‑world data, trials, and tiorotinib insights.
Chieh-Lung Cheng, MD, PhD
Advertisement
Articles by Chieh-Lung Cheng, MD, PhD
Experts debate BTK inhibitors for primary CNS lymphoma, sharing trial and real-world insights on tirabrutinib and options for relapsed disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
2
FDA Approves Rusfertide for Polycythemia Vera
3
DESTINY-Breast05 Safety Analysis Clarifies ILD and Radiation Risks With T-DXd in HER2+ Breast Cancer
4
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
5